SAN FRANCISCO, Nov. 28 – Millennium Pharmaceuticals on Tuesday announced it had begun Phase I clinical trials for its first molecule directed against a genomically- derived target for metabolic disease.
The compound, called MLN4760, was synthesized by Millennium and was designed with the hope of providing a treatment for obesity. Millennium, based in Cambridge, Mass., partnered with Abbott Park, Ill.-based Abbott Laboratories in the development of the drug.
“With MLN4760 entering human trials, we realize an important company goal of bringing our first genomically-derived target into clinical development,” Robert Tepper, chief scientific officer, at Millennium, said in a statement. “In addition, MLN4760 represents a major milestone in the Abbott-Millennium partnership and highlights the strength of the alliance in using proprietary genomic and chemical technology platforms to discover and validate druggable targets and to move them through an expedited drug discovery process.”
The Phase I clinical trial is the first step in assessing the safety and efficacy of the drug in humans.